ArticleThe Journal of biological chemistry2019
Pharmacologically diverse antidepressants facilitate TRKB receptor activation by disrupting its interaction with the endocytic adaptor complex AP-2.
Article in The Journal of biological chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- The Mechanisms Behind Rapid Antidepressant Effects of Ketamine: A Systematic Review With a Focus on Molecular Neuroplasticity.Frontiers in psychiatry · 2022Pooled it
- Fingolimod Acutely Facilitates the Activation of TRKB in a BDNF-dependent Manner.Cellular and molecular neurobiology · 2026Article
- Ketamine metabolism via hepatic CYP450 isoforms contributes to its sustained antidepressant actions.Neuropharmacology · 2024Article
- Article
- Anti-neuroinflammatory effect of hydroxytyrosol: a potential strategy for anti-depressant development.Frontiers in pharmacology · 2024Article
- Mutation in the TRKB Cholesterol Recognition Site that blocks Antidepressant Binding does not Influence the Basal or BDNF-Stimulated Activation of TRKB.Cellular and molecular neurobiology · 2023Article
- Psychedelics promote plasticity by directly binding to BDNF receptor TrkB.Nature neuroscience · 2023Article
- Activation of TrkB in Parvalbumin interneurons is required for the promotion of reversal learning in spatial and fear memory by antidepressants.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2023Article
- A synaptic molecular dependency network in knockdown of autism- and schizophrenia-associated genes revealed by multiplexed imaging.Cell reports · 2023Article
- Genetic knockout ofFrontiers in cellular neuroscience · 2023Article
- Receptor-Independent Anti-Ferroptotic Activity of TrkB Modulators.International journal of molecular sciences · 2022Article
- Mechanisms of ketamine and its metabolites as antidepressants.Biochemical pharmacology · 2022Review
- Overview of the Neuroprotective Effects of the MAO-Inhibiting Antidepressant Phenelzine.Cellular and molecular neurobiology · 2022Review
- BDNF receptor TrkB as the mediator of the antidepressant drug action.Frontiers in molecular neuroscience · 2022Review
- Facilitation of TRKB Activation by the Angiotensin II Receptor Type-2 (AT2R) Agonist C21.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Transient Stimulation with Psychoplastogens Is Sufficient to Initiate Neuronal Growth.ACS pharmacology & translational science · 2021Article
- Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications.Pharmacological reviews · 2021Review
- Article
- Chondroitinase and Antidepressants Promote Plasticity by Releasing TRKB from Dephosphorylating Control of PTPσ in Parvalbumin Neurons.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2021Article
- Uncovering the Underlying Mechanisms of Ketamine as a Novel Antidepressant.Frontiers in pharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several antidepressant drugs activate tropomyosin-related kinase B (TRKB) receptor, but it remains unclear whether these compounds employ a common mechanism for TRKB activation. Here, using MS, we found that a single intraperitoneal injection of fluoxetine disrupts the interaction of several proteins with TRKB in the hippocampus of mice. These proteins included members of adaptor protein complex-2 (AP-2) involved in vesicular endocytosis. The interaction of TRKB with the cargo-docking μ subunit of the AP-2 complex (AP2M) was confirmed to be disrupted by both acute and repeated fluoxetine treatments. Of note, fluoxetine disrupted the coupling between full-length TRKB and AP2M, but not the interaction between AP2M and the TRKB C-terminal region, indicating that the fluoxetine-binding site in TRKB lies outside the TRKB:AP2M interface. ELISA experiments revealed that in addition to fluoxetine, other chemically diverse antidepressants, such as imipramine, rolipram, phenelzine, ketamine, and its metabolite 2
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.